Balyasny Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-52,900
| Closed | -$9.31M | – | 2910 |
|
|
2025
Q4 | $9.31M | Buy |
52,900
+48,000
| +980% | +$7.84M | 0.01% | 1061 |
|
|
2025
Q3 | $686K | Buy |
+4,900
| New | +$662K | ﹤0.01% | 2259 |
|
|
2025
Q1 | – | Sell |
-1,400
| Closed | -$214K | – | 2800 |
|
|
2024
Q4 | $214K | Sell |
1,400
-14,600
| -91% | -$2.46M | ﹤0.01% | 2512 |
|
|
2024
Q3 | $3.1M | Buy |
+16,000
| New | +$3.35M | 0.01% | 1480 |
|
|
2023
Q3 | – | Sell |
-26,000
| Closed | -$7.41M | – | 2267 |
|
|
2023
Q2 | $7.41M | Buy |
+26,000
| New | +$7.74M | 0.02% | 910 |
|
|
2022
Q2 | – | Sell |
-142,000
| Closed | -$29.9M | – | 2751 |
|
|
2022
Q1 | $29.9M | Buy |
142,000
+49,000
| +53% | +$10.7M | 0.09% | 287 |
|
|
2021
Q4 | $22.3M | Sell |
93,000
-26,000
| -22% | -$6.69M | 0.08% | 366 |
|
|
2021
Q3 | $33.7M | Buy |
119,000
+96,000
| +417% | +$31.5M | 0.14% | 199 |
|
|
2021
Q2 | $7.96M | Sell |
23,000
-3,000
| -12% | -$909K | 0.04% | 576 |
|
|
2021
Q1 | $7.27M | Sell |
26,000
-8,000
| -24% | -$2.16M | 0.04% | 571 |
|
|
2020
Q4 | $8.32M | Sell |
34,000
-30,500
| -47% | -$7.87M | 0.05% | 491 |
|
|
2020
Q3 | $18.3M | Buy |
+64,500
| New | +$18M | 0.13% | 211 |
|
|
2020
Q1 | – | Sell |
-70,000
| Closed | -$20.8M | – | 1169 |
|
|
2019
Q4 | $20.8M | Buy |
+70,000
| New | +$19.4M | 0.12% | 254 |
|
|
2019
Q3 | – | Sell |
-75,000
| Closed | -$17.9M | – | 1179 |
|
|
2019
Q2 | $17.9M | Buy |
75,000
+3,000
| +4% | +$693K | 0.11% | 247 |
|
|
2019
Q1 | $17M | Buy |
+72,000
| New | +$22.7M | 0.11% | 260 |
|
|
2018
Q3 | – | Sell |
-24,000
| Closed | -$6.97M | – | 1672 |
|
|
2018
Q2 | $6.97M | Sell |
24,000
-163,500
| -87% | -$46M | 0.03% | 587 |
|
|
2018
Q1 | $51.3M | Buy |
187,500
+2,500
| +1% | +$776K | 0.21% | 115 |
|
|
2017
Q4 | $58.9M | Buy |
+185,000
| New | +$59.3M | 0.18% | 142 |
|
|
2017
Q3 | – | Sell |
-70,000
| Closed | -$19M | – | 1882 |
|
|
2017
Q2 | $19M | Buy |
+70,000
| New | +$18.5M | 0.08% | 330 |
|
|
2017
Q1 | – | Sell |
-103,200
| Closed | -$27M | – | 1588 |
|
|
2016
Q4 | $27M | Buy |
+103,200
| New | +$30.6M | 0.14% | 198 |
|
|
2016
Q3 | – | Sell |
-250,000
| Closed | -$60.5M | – | 1013 |
|
|
2016
Q2 | $60.5M | Sell |
250,000
-30,000
| -11% | -$7.91M | 0.39% | 53 |
|
|
2016
Q1 | $72.9M | Buy |
+280,000
| New | +$74M | 0.43% | 43 |
|
|
2015
Q2 | – | Sell |
-25,000
| Closed | -$10.6M | – | 1145 |
|
|
2015
Q1 | $10.6M | Sell |
25,000
-5,000
| -17% | -$1.97M | 0.09% | 334 |
|
|
2014
Q4 | $10.2M | Buy |
+30,000
| New | +$9.71M | 0.09% | 293 |
|
Other funds holding BIIB
VCM
VPM
Balyasny Asset Management's BIIB Position: Q1 2026 in Review
Balyasny Asset Management increased its Biogen (BIIB) stake by 6.9% in Q1 2026, buying an estimated $7.76M and bringing the position to 650,046 shares worth $119M. The position accounts for 0.15% of the portfolio, ranked #140.
Balyasny Asset Management first reported a position in BIIB in Q4 2014 and has held it in 42 quarters since. The position peaked at $174M in Q4 2017. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Balyasny Asset Management held 650,046 shares of Biogen worth $119M as of Q1 2026.
- Balyasny Asset Management bought 42,093 Biogen shares in Q1 2026, an estimated $7.76M.
- Biogen made up 0.15% of Balyasny Asset Management's portfolio in Q1 2026, its #140 holding.
- Balyasny Asset Management first reported a position in Biogen in Q4 2014 and has held it in 42 quarters since.
- Balyasny Asset Management's Biogen position peaked at $174M in Q4 2017.
- 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.